Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,733 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,059 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT05526846 | Introducing a Plant-Based Diet for Patients With Colorectal Diseases | unknown | N/A | 60 | Stanford UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06334458 | Epigenomic and Machine Learning Models to Predict Pancreatic Cancer(IMAGene) | unknown | N/A | 170 | European Institute of OncologyOTHER | 4 | Mar 28, 2024 | clinicaltrials |
| NCT06335147 | PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer | unknown | N/A | 23 | Henan Cancer HospitalOTHER_GOV | 0 | Mar 28, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05170802 | Pancreatic Cancer & Surgical Resection | unknown | — | 30 | Methodist Health SystemOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT03835663 | The Bacterial Composition of the Stomach in Reflux Disease | unknown | — | 100 | Imperial College LondonOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT04543695 | A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer | unknown | Phase 2 | 255 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT05767697 | Genomics and Prognosis in GI Cancers | unknown | — | 1,000 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06202716 | Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore | unknown | Phase 2 | 50 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328283 | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05823272 | ONS in Gastric Cancer After Total Gastrectomy | unknown | N/A | 60 | Jinling Hospital, ChinaOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05305820 | Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy(PANO) | unknown | N/A | 36 | Dublin City UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06322563 | Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06008522 | Safety and Feasibility of Immuno-OCT(DETOUR) | unknown | N/A | 15 | University Medical Center GroningenOTHER | 0 | Mar 20, 2024 | clinicaltrials |
| NCT06319404 | Immune Function of Colorectal Cancer Lymph Nodes | unknown | — | 500 | Shanxi Province Cancer HospitalOTHER | 0 | Mar 20, 2024 | clinicaltrials |
| NCT06320301 | Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC) | unknown | Phase 2 | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06322147 | Chemotherapy With Cetuximab as Conversion Therapy in RAS/BRAF WT Unresectable Liver Metastasis Right-sided Colon Cancer | unknown | — | 50 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT05420259 | Combined Exercise and Nutritional Intervention in GI Cancer Patients | unknown | N/A | 68 | Hospital Beatriz ÂngeloOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06225622 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | unknown | Phase 1 | 78 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06304987 | Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and PCSK9 Inhibitor for pMMR/MSS Locally Advanced Mid-low Rectal Cancer | unknown | Phase 2 | 50 | Beijing Friendship HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06318234 | PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer | unknown | — | 32 | Xiao ChenOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06316466 | Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis | unknown | — | 360 | jingxueOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06068127 | G-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through(GESOM) | unknown | — | 30 | Institute for Clinical and Experimental MedicineOTHER_GOV | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06302751 | A Mobile Application to Improve Postoperative Outcomes in Colorectal Cancer(RAISe-Care) | unknown | N/A | 600 | Istituto Clinico HumanitasOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06310902 | Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients | unknown | — | 40 | Fujian Medical University Union HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06311279 | End to End Versus Side to End Anastomosis After Anterior Resection of Cancer Rectum | unknown | N/A | 20 | Sohag UniversityOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06312839 | Preoperative Arterial Embolization Before Oncologic Esophagectomy as a Technique for Ischemic Gastric Conditioning | unknown | — | 50 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04249739 | Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive | unknown | Phase 2 | 93 | Samsung Medical CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04024358 | A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer(VANISSh) | unknown | — | 500 | Massimo FalconiOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04245644 | Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study(CAOS) | unknown | — | 800 | Massimo FalconiOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT06304597 | Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy(PREDICT) | unknown | Phase 1 | 18 | University Medical Center GroningenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06305169 | Measuring the Negative Predictive Value and Specificity of Serum Biomarkers in Gastric Cancer | unknown | — | 440 | Sandwell & West Birmingham Hospitals NHS TrustOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06300489 | Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer | unknown | Phase 1 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06301828 | Endostar Combined With SBRT and Envafolimab in the Treatment of Advanced Gastrointestinal Tumors | unknown | Phase 2 | 16 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT03936530 | Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer | unknown | — | 432 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05022030 | First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes(CAPCET) | unknown | Phase 2 | 150 | West China HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06036745 | Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen | unknown | Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2024source: clinicaltrials